TY - JOUR T1 - Regioselective Hydroxylation of Omeprazole Enantiomers by Bacterial CYP102A1 Mutants JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1493 LP - 1497 DO - 10.1124/dmd.114.058636 VL - 42 IS - 9 AU - Sang Hoon Ryu AU - Bo-Yeon Park AU - So-Young Kim AU - Sun-Ha Park AU - Hyun-Jin Jung AU - Min Park AU - Ki Deok Park AU - Taeho Ahn AU - Hyung-Sik Kang AU - Chul-Ho Yun Y1 - 2014/09/01 UR - http://dmd.aspetjournals.org/content/42/9/1493.abstract N2 - A large set of Bacillus megaterium CYP102A1 mutants are known to metabolize various drugs to form human metabolites. Omeprazole (OMP), a proton pump inhibitor, has been widely used as an acid inhibitory agent for the treatment of gastric acid hypersecretion disorders. It is primarily metabolized by human CYP2C19 and CYP3A4 to 5′-OH OMP and a sulfone product, respectively. It was recently reported that several CYP102A1 mutants can oxidize racemic and S-OMP to 5′-OH OMP and that these mutants can further oxidize 5′-OH racemic OMP to 5′-COOH OMP. Here, we report that the S- and R-enantiomers of OMP are hydroxylated by 26 mutants of CYP102A1 to produce 1 major metabolite (5′-OH OMP) regardless of the chirality of the parent substrates. Although the binding of R-OMP to the CYP102A1 active site caused a more apparent change of heme environment compared with binding of S-OMP, there was no correlation between the spectral change upon substrate binding and catalytic activity of either enantiomer. The 5′-OH OMP produced from racemic, S-, and R-OMP could be obtained with a high conversion rate and high selectivity when the triple R47L/F87V/L188Q mutant was used. These results suggest that bacterial CYP102A1 mutants can be used to produce the human metabolite 5′-OH OMP from both the S- and R-enantiomers of OMP. ER -